Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency

Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron‐deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR‐HF and CONFIRM‐HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time.

[1]  P. Ponikowski,et al.  Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.

[2]  P. Ponikowski,et al.  The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study , 2011, European heart journal.

[3]  J. Spertus,et al.  Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[4]  P. Ponikowski,et al.  Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.

[5]  D. Girelli,et al.  Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting , 2020, Internal and Emergency Medicine.

[6]  P. Ponikowski,et al.  Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction , 2020, European journal of heart failure.

[7]  D. DeMets,et al.  Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction , 2019, Circulation.

[8]  D. Silverberg,et al.  Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients , 2019, ESC heart failure.

[9]  S. Bhandari,et al.  Intravenous Irons: From Basic Science to Clinical Practice , 2018, Pharmaceuticals.

[10]  F. Verbrugge,et al.  Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction , 2018, Acta cardiologica.

[11]  B. Rocha,et al.  The Burden of Iron Deficiency in Heart Failure: Therapeutic Approach. , 2018, Journal of the American College of Cardiology.

[12]  P. Ponikowski,et al.  Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis , 2018, European journal of heart failure.

[13]  P. Ponikowski,et al.  Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency , 2017, Circulation.

[14]  Akshay S. Desai,et al.  Health-Related Quality of Life Outcomes in PARADIGM-HF , 2017, Circulation. Heart failure.

[15]  Beat Flühmann,et al.  The similarity question for biologicals and non-biological complex drugs. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[17]  P. Ponikowski,et al.  Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. , 2014, International journal of cardiology.

[18]  D. Goff,et al.  Cardiovascular Health : The Importance of Measuring Patient-Reported Health Status A Scientific Statement From the American Heart Association , 2022 .

[19]  Vinod P. Shah,et al.  Different Pharmaceutical Products Need Similar Terminology , 2013, The AAPS Journal.

[20]  P. Ponikowski,et al.  Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. , 2011, Journal of cardiac failure.

[21]  K. Swedberg,et al.  Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. , 2011, European Heart Journal.

[22]  O. Nielsen,et al.  Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study , 2010 .

[23]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[24]  W. Kraus,et al.  Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[25]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.

[26]  P. Duarte,et al.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.

[27]  A. Bolger,et al.  Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.

[28]  H. Krumholz,et al.  Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.

[29]  J. Spertus,et al.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.

[30]  J. Hutton,et al.  Number needed to treat: properties and problems , 2000 .